Despite expected EPS rise, Zhejiang Medicine's P/E ratio sta...

Despite expected EPS rise, Zhejiang Medicine's P/E ratio stays below market, indicating shareholder skepticism. Future earnings could be volatile with potential unseen threats preventing P/E ratio from reflecting positive outlook.